New TB drug cocktail shows promise in early trial

NCT ID NCT05382312

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called GSK3036656 in combination with other tuberculosis medications in 127 adults with newly diagnosed, drug-sensitive pulmonary TB. Participants received one of several two-drug combinations or standard care for 14 days, then switched to standard treatment. The goal was to measure how quickly the combinations killed TB bacteria in sputum and to check for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3036656 (an experimental drug) combined with other tuberculosis drugs (bedaquiline, delamanid, BTZ-043, pretomanid, linezolid, moxifloxacin) or standard care
What this could lead to: If successful, this could point toward shorter, more effective treatment combinations for drug-sensitive tuberculosis.
What could go wrong: This is an early Phase 2A trial with only 127 participants and a short 14-day treatment period. Results may not translate to long-term cure or apply to all TB patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Locations

GSK Investigational Site

Bellville, 7530, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.